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Abstract
Introduction: Numerous factors influence the development of gastrointestinal (GI) cancer. The insulin-like growth factor
(IGF) axis plays a role in embryonic and postnatal growth and tissue repair. Elevated levels of IGFs, low levels of IGF binding
proteins (IGFBPs) and over-expression of IGF receptor (IGFR-I) were associated with several stages of cancer. Here, the
prevalence of the single nucleotide polymorphisms (SNPs) rs6214 in the IGF type I (IGF-I) gene and rs6898743 in the growth
hormone receptor (GHR) gene in patients with GI cancer and controls was studied.
Materials & Methods: In this Dutch case-control study, DNA isolated from blood of 1,457 GI cancer patients; 438 patients
with head and neck cancer (HNC), 475 with esophageal cancer (EC) and 544 with colorectal cancer (CRC) and 1,457 matched
controls, was used to determine the rs6214 and rs6898743 genotypes by polymerase chain reaction. The association
between these SNPs and GI cancer, HNC, esophageal adenocarcinoma (EAC), esophageal squamous-cell carcinoma (ESCC)
and proximal or distal CRC was studied. Odds ratios (ORs) with 95% confidence interval (95% CI) were calculated via
unconditional logistic regression.
Results: Overall for GI cancer, the ORs for SNPs rs6214 and rs6898743 were approximately 1.0 (p-value.0.05), using the
most common genotypes GG as reference. An OR of 1.54 (95% CI, 1.05–2.27) was found for EC for genotype AA of rs6214.
The ORs for EAC were 1.45 (95% CI, 1.04–2.01) and 1.71 (95% CI, 1.10–2.68), for genotypes GA and AA, respectively.
Genotype GC of rs6898743 showed an OR of 0.47 (95% CI, 0.26–0.86) for ESCC.
Conclusion: The A allele of SNP rs6214 in the IGF-I gene was associated with EAC, and with HNC in women. The GC
genotype of rs6898743 in the GHR gene was negatively associated with ESCC.
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Introduction
Worldwide, cancer is one of the most prevalent causes of death
[1]. In 2011, the overall incidence of cancer in the Netherlands
was 100,577 cases, approximately 20% did develop gastrointes-
tinal (GI) cancer [2]. The number of new patients with GI cancer
is increasing in the Netherlands over the past 20 years [2].
Ten to twenty percent of the GI cancers are hereditary [3].
There are several other factors that play a role in the development
of GI cancer, including age, gender, smoking, physical activity and
obesity [4,5]. Also dietary factors, such as intake of alcohol,
consumption of low amounts of vegetables and fruits, excessive
consumption of red meat, and many other dietary factors may
have an impact on the development of GI cancer [5]. In addition,
risk modulating genetic factors with low penetrance, such as
numerous single nucleotide polymorphisms (SNPs), may be
involved in the development of GI cancer.
In this respect the insulin-like growth factor (IGF) axis may be of
interest, since the evidence that it is involved in several stages of
cancer is increasing [6–8]. The IGF axis plays a role in embryonic
and postnatal growth, in tissue repair and many other important
processes [6,9,10]. Elevated levels of IGFs, low levels of IGF
binding proteins (IGFBPs) in the circulation and over-expression
of IGF receptor type I (IGFR-I) were associated with cancer
[7,11]. In vitro studies indicated that several components of the IGF
axis induce mitosis and prevents apoptosis in cancer cells [12,13].
IGF is mainly produced by the liver and it is mediated by the
growth hormone (GH) family. The predominant isoform of this
somatotropin family is growth hormone 1 (GH1). The growth
hormone releasing hormone (GHRH), secreted by the hypothal-
amus, regulates the production of GH in the adenohypophysis of
the pituitary gland [14]. The GH binds to the growth hormone
receptor (GHR) in the liver and other target tissues. This
interaction promotes the synthesis of IGF-I and IGF-II [15].
IGF is able to bind to the members of the IGFBP family [16].
Most IGFs circulating in the blood stream are bound to IGFBPs
with a high binding affinity, resulting in an increased half-life of
the IGFs. The majority of IGFs in the circulation bind to IGFBP-
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3, an acid labile subunit (ALS) complex [17]. Numerous factors,
including hormones, diet, ethnicity, age and sex, influence the
levels of IGFs and IGFBP-3 in serum and tissues [18].
In addition to the IGFBP family members, IGF-I and IGF-II
bind to the two types of IGF receptors, IGFR-I and IGFR-II.
IGFR-I, a transmembrane tyrosine kinase receptor, is expressed
throughout the human body. Both types of IGF are able to interact
with this receptor with different binding affinities. Activation of the
IGFR-I related pathway may lead to proliferation, differentiation,
migration and prevention of a cell from going into apoptosis [8].
The function of IGFR-II, a cation-independent mannose-6-
phosphate receptor, is less clear. This receptor interacts with IGF-I
as well as with IGF-II. The binding of this receptor with IGF-I is
weak, whereas IGFR-II has a high binding affinity for IGF-II. In
contrast to IGFR-I, these interactions do not lead to activation of
cell signaling pathways. The main function of this receptor is
probably the sequestering of IGF-II and eventually degradation of
this protein [9].
Several genetic variants in the components of the IGF axis were
already investigated in association with cancer risk. McElholm
et al. analyzed 102 SNPs in the IGF axis [17] and characterized
three genetic variants that appeared to be associated with
esophageal adenocarcinoma: rs6214 in the IGF-I gene,
rs6898743 in the GHR gene and a CA-repeat in the promoter
region (59-UTR) of the IGF-I gene, the latter variant however
being very rare. The association between the SNPs rs6214 and
rs6898743 and other GI cancers was not investigated yet.
The SNP rs6214 (c.*2716G.A) resides on the IGF-I gene [19].
This gene is located on the long arm of chromosome 12 at position
23.2 and consists of six exons [20]. The SNP rs6214 is located in
the three prime untranslated region (39-UTR), which has an
important role in the translation, localization and stability of
mRNA [21–23]. In Europe, the allele frequencies of the G and A
alleles are 55% and 45%, respectively [24].
The SNP rs6898743 (c.71-26648G.C) is an intronic SNP in
the GHR gene, localized on chromosome 5 [17]. In the European
population, approximately 75% and 25% are G and C alleles,
respectively [25].
In this study, the prevalence of the SNPs rs6214 and rs6898743
in patients with GI cancer and controls were investigated in a
Dutch population.
Materials and Methods
Study Population
For this population-based case-control study, whole blood or
healthy tissue of Caucasian patients with GI cancer and controls
was collected between 2002 and 2013 at several hospitals in the
Netherlands. Enrollment criteria were that cases were included in
the order of entry to the hospitals, and only patients who’s
diagnosis was confirmed by a pathologist, were included in the
study. All subsequent patients who were willing to participate, gave
their written informed consent. The investigations were approved
by the Medical Ethical Review Committees of the Maastricht
University Medical Center and Radboud University Nijmegen
Medical Center (RUNMC).
The blood and tissue samples of patients with CRC or EC were
obtained from the RUNMC and the Gelderse Vallei Hospital,
Ede. Patients with EC were also included at the Canisius-
Wilhelmina Hospital Nijmegen and the Rijnstate Hospital,
Arnhem. The blood samples of the healthy controls, for
comparison with the CRC and EC patient groups, were recruited
from the Nijmegen area, by advertisement in local papers. Blood
of patients with HNC was collected at the University Hospital
Maastricht. Healthy controls for this group of patients were
recruited from the blood bank, Maastricht area. Controls were
matched with the patients with respect to age and gender.
EC was classified by a pathologist as the histological subtypes
esophageal squamous-cell carcinoma (ESCC) or esophageal
adenocarcinoma (EAC). In patients with CRC, the location of
the tumor was identified as being in the proximal (cecum, colon
ascendens, colon transversum) or distal (colon descendens, sigmoid
colon, rectum) part of the colon.
Blood was stored at 220uC at the laboratory of the Department
of Gastroenterology, RUNMC. Controls were matched to patients
by gender, age, ethnicity and recruiting area to create two
comparable groups.
DNA Isolation
In patients, DNA was isolated from blood or healthy tissue,
obtained after resection of the tumor. In controls DNA was
isolated from blood. For DNA isolation the High Pure PCR
Template Preparation Kit (Roche Diagnostics GmbH, Mann-
heim, Germany) was used, according to the protocol of the
manufacturer. DNA samples were stored at 4uC until use.
Table 1. Sequences of primers and probes, including the optimal annealing temperature and MgCl2-concentration.
SNP (Gene) Primer/Probe Sequence 59 R 39
Annealing
Temperature [MgCl2]
rs6214 (IGF-I) F primer CTCAACAAAACTTTATAGGCAGTC 60.0uC 5 mM
R primer GCAGTGCATCTTTCAGCTT
WT probe CTGCAGACTTAACGTGTTTTCTGTCATAG
VAR probe CTGCAGACTTAACATGTTTTCTGTCATAG
rs6898743 (GHR) F primer TACCATTTGCATGGAATATC 56.5uC 4 mM
R primer AGCTTAAATCTGTCCCTATC
WT probe ATCACTTACCTTTTAGTGTATGTATGTACT
VAR probe ATCACTTACCTTTTACTGTATGTATGTACT
F = forward; R = reverse; WT =wild type; VAR= variant; the bold underlined letters represent the wild type (most common) allele (Allele 1) and the variant allele (Allele 2)
in the WT probe and VAR probe, respectively.
doi:10.1371/journal.pone.0090916.t001
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Genotyping
The rs6214 and rs6898743 polymorphisms were established by
means of real-time polymerase chain reaction (RT-PCR) tech-
niques. A specific set of primers, which flank the region of the
SNPs, was used to amplify the DNA. In the TaqMan assay, two
labeled probes with a fluorophore at the 59end and a quencher at
the 39 end, were added to the PCR mixture. Primers and probes
were designed for each SNP, using the Beacon Designer 7.0
software (PREMIER Biosoft, Palo Alto, California, USA). Primers
and TaqMan probes were prepared by Sigma-Aldrich Chemie
BV. (Zwijndrecht, the Netherlands) and were checked for
polymorphisms in their binding sites using SNPCheck version 3
(https://ngrl.manchester.ac.uk/SNPCheckV3/snpcheck.htm).
The sequences of the primers and probes are given in Table 1.
Table 2. Characteristics of the study population.
Cancer subtype Characteristics Patients with GI cancer Controls
Head and neck n 438 438
Male (%) 345 (78.8) 345 (78.8)
Female (%) 93 (21.2) 93 (21.2)
Mean age 6 SD (years)1 60.9611.3 56.566.7
Esophageal n 475 475
Male (%) 384 (80.8) 384 (80.8)
Female (%) 81 (19.2) 81 (19.2)
Mean age 6 SD (years) 65.1611.0 65.1611.3
Histological subtype
EAC 355 –
ESCC 112 –
Unknown 7 –
Colorectal n 544 544
Male (%) 325 (59.7) 325 (59.7)
Female (%) 219 (40.3) 219 (40.3)
Mean age 6 SD (years) 65.0611.7 64.7612.5
Location
Proximal 156 –
Distal 366 –
Unknown 21 –
Total GI cancer n 1,457 1,457
Male (%) 1,054 (72.3) 1,054 (72.3)
Female (%) 403 (27.7) 403 (27.7)
Mean age 6 SD (years)2 63.8611.5 62.4611.3
n = number of patients or controls; GI, gastrointestinal; SD = standard deviation; EAC = esophageal adenocarcinoma; ESCC = esophageal squamous cell carcinoma;
1p-value mean age= 0.000;
2p-value mean age= 0.001.
doi:10.1371/journal.pone.0090916.t002
Table 3. Genotype distribution in patients with gastrointestinal cancer and controls.
SNP (Gene) Genotype Patients with GI cancer Controls OR (95% CI) ** p-value
n (%)* n (%)*
rs6214 (IGF-I) GG 491 (34.0) 528 (36.3) Reference
GA 709 (49.1) 706 (48.5) 1.08 (0.92–1.27) 0.339
AA 245 (17.0) 221 (15.3) 1.20 (0.96–1.49) 0.111
rs6898743 (GHR) GG 844 (58.5) 859 (59.0) Reference
GC 518 (35.9) 522 (35.9) 1.01 (0.87–1.18) 0.896
CC 81 (5.6) 75 (5.2) 1.10 (0.79–1.53) 0.558
*Note that some patients or controls are missing because of failure of the genotyping.
**Adjusted for age.
GI, gastrointestinal; OR, odds ratio; CI, confidence interval.
doi:10.1371/journal.pone.0090916.t003
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The 6-fluorescein amidite (6-FAM) and hexachloro-fluorescein
amidite (HEX) were covalently bound to the probes for the most
common alleles and the less common alleles, respectively. The
Black Hole Quencher-1 (BHQ1), was used which was bound to
the 39-end of the TaqMan probe. The RT-PCRs were performed
with the CFX96 Real-Time PCR detection system (Bio-Rad
Laboratories Inc, Hercules, California, USA) and the results were
analyzed with the data analysis software Bio-Rad CFX Manager
2.0 (Bio-Rad Laboratories Inc).
Statistical Analyses
The results from the RT-PCRs, genotype and allele frequency
distributions, were analyzed by using IBM SPSS Statistics software
version 20 (International Business Machines Corp., Armonk, New
York, USA).
The equality of the mean age was tested using the independent-
samples t-test. In the analysis, age and gender were considered as
confounders. Odds ratios (ORs) with their 95% confidence
intervals (95% CIs) were calculated for the genotypes and for
the alleles frequencies by performing unconditional as well as
conditional logistic regression analyses. Homozygosity for the most
common allele was taken as reference.
When the mean age between the patient (sub)group and the
control group was significantly different, the ORs calculated with
the unconditional logistic regression were corrected for this
variable. Results with a p-value ,0.05 were considered statistically
significant.
Results
The characteristics of the study population and the number of
subjects per GI cancer subtype are summarized in Table 2. In this
study, 1,457 patients with GI cancer and 1,457 controls were
included, aged between 16 and 95 years. The mean age of the GI
cancer patient and control groups was 63.8611.5 and 62.4611.3
years, respectively (p-value = 0.001).
In the sub-analyses, in which the association between the SNPs
and the development of each cancer subtype was investigated, the
mean age between the HNC patients and the corresponding
control group was significantly different (p-value = 0.0001).
The genotype distribution for SNPs rs6214 and rs6898743 in
patients with GI cancer and controls are presented in Table 3. For
the SNPs rs6214 and rs6898743, the distribution of the genotypes
in the overall GI cancer patient group, in the GI cancer sub-
groups as well as in the control groups did not deviate from the
Hardy-Weinberg equilibrium (all p-values .0.05), except for the
ESCC patient sub-group, which showed a p-value of 0.003 for
SNP rs6898743.
For both SNPs, no associations with GI cancer were seen (ORs
between 1.01 and 1.20, p-values .0.05), except for a significant
over-expression of the GA genotype of rs6214 in female patients
(OR 1.38, 95% CI 1.01–1.87).
Table 4 summarizes the genotype distribution and the ORs
(95% CI) for SNPs rs6214 and rs6898743 per cancer subtype. In
this sub-analysis, a significant association with EC (OR 1.54, 95%
CI, 1.05–2.27) was found for genotype AA of rs6214 (p-
value = 0.029), whereas the GA genotype showed a non-significant
OR of 1.27 (95% CI 0.96–1.69). The A-allele was significantly
more present in the patient group (p-value = 0.021). Analyzed
according to gender, genotype AA of rs6214 in men showed an
even higher OR of 1.68 (95% CI, 1.09–2.59) with a p-value of
0.019.
No significant associations were found between patients with
HNC or CRC and controls for the genotypes of both SNPs.
However, for HNC in women an OR of 2.19 (95% CI, 1.09–4.39)
was found for the GA genotype of rs6214, whereas an OR of 0.08,
Table 4. Genotype distribution and ORs (95% CI) per cancer subtype, for the genotypes of SNPs rs6214 and rs6898743.
Cancer subtype SNP (Gene) Genotype Patients Controls OR (95% CI) p-value
n (%) n (%)
HNC rs6214 (IGF-I) GG 153 (35.3) 147 (33.6) Reference
GA 210 (48.5) 214 (49.0) 0.91 (0.67–1.24)* 0.550
AA 70 (16.2) 76 (17.4) 0.88 (0.58–1.32)* 0.527
rs6898743 (GHR) GG 246 (56.9) 263 (60.0) Reference
GC 164 (38.0) 156 (35.6) 1.08 (0.81–1.44)* 0.588
CC 22 (5.1) 19 (4.3) 1.16 (0.61–2.23)* 0.654
EC rs6214 (IGF-I) GG 155 (33.0) 187 (39.5) Reference
GA 230 (49.0) 221 (46.6) 1.27 (0.96–1.69) 0.096
AA 84 (17.9) 66 (13.9) 1.54 (1.05–2.27) 0.029
rs6898743 (GHR) GG 271 (57.9) 273 (57.6) Reference
GC 164 (35.0) 181 (38.2) 0.92 (0.70–1.20) 0.524
CC 33 (7.1) 20 (4.2) 1.67 (0.93–2.99) 0.085
CRC rs6214 (IGF-I) GG 183 (33.7) 194 (35.7) Reference
GA 269 (49.5) 271 (49.8) 1.04 (0.80–1.36) 0.750
AA 91 (16.8) 79 (14.5) 1.21 (0.84–1.74) 0.311
rs6898743 (GHR) GG 327 (60.2) 323 (59.4) Reference
GC 190 (35.0) 185 (34.0) 1.02 (0.79–1.32) 0.868
CC 26 (4.8) 36 (6.6) 0.73 (0.43–1.23) 0.235
*Adjusted for age; OR, odds ratio; CI, confidence interval; HNC, head and neck cancer; EC, esophageal carcinoma; CRC, colorectal cancer.
doi:10.1371/journal.pone.0090916.t004
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95% CI, 0.01–0.65 was found for the CC genotype of SNP
rs6898743. The ORs calculated for the rs6214 and rs6898743
genotypes, per histological subtype of EC are shown in Table 5.
An OR of 1.45 (95% CI, 1.04–2.01) was found for GA
heterozygotes of rs6214 in EAC (p-value = 0.028), whereas
homozygotes for the variant allele AA showed an OR of 1.71
(95% CI, 1.10–2.68; p-value = 0.018). In men with genotype AA of
rs6214, the association was even stronger (OR 1.87, 95% CI,
1.14–3.07; p = 0.013). The A-allele was significantly more present
in the EAC patient group as well as in the male sub-group (p-
values 0.008 and 0.009, respectively).
For SNP rs6898743, an inverse association with ESCC was
noticed for genotypes GC (OR 0.47, 95% CI, 0.26–0.86) with a p-
value of 0.014. In contrast, the homozygote variant CC genotype
revealed an OR of 2.54 (95% CI, 0.66–9.81). However in these
CC subgroups the number of individuals are very small. Likewise,
a significant inverse association with ESCC was found in men with
genotype GC (OR 0.31, 95% CI, 0.15–0.66; p=0.002). No
significant associations were found when CRC patients were
analyzed according to tumor localization, either proximal or distal
(Table 5).
The main results of this study are visualized in Figure 1.
Discussion
This population-based case-control study was performed to
investigate the role of the IGF associated SNPs rs6214 and
rs6898743 in the development of gastrointestinal cancer. The
SNPs rs6214 and rs6898743 were not found associated with GI
cancer, however in GI cancer subgroups, some interesting
associations were noticed.
Genotype AA of rs6214 in the IGF-I gene was associated with
EC, but this risk modifying effect of the rs6214 A allele was mainly
the result of an association with the histological subgroup of EAC;
individuals bearing the GA or AA genotypes showed relative risks
of 1.45 and 1.71, respectively. The SNP rs6214 has been
investigated in several previous studies on GI cancer risk. Feik
et al. reported a significantly higher risk of CRC for carriers of
genotype AA [26]. A similar trend was seen in our study but no
significance was reached. This difference could be explained by
the fact that the study population of Feik et al. only contained 178
CRC patients. Moreover, their ORs were adjusted for gender, age
and body mass index (BMI), whereas BMI was not involved in our
study.
McElholm et al. reported a significant decreased risk of
Barrett’s esophagus (BE) for the AA genotype of rs6214 in an
Irish study population (OR=0.43, 95% CI 0.24–0.75) [17]. BE is
an abnormal replacement in the esophagus of squamous
Table 5. Genotype distribution and ORs (95% CI) for the genotypes of SNPs rs6214 and rs6898743 in patients with EAC, ESCC,
proximal CRC or distal CRC.
Cancer subtype SNP (Gene) Genotype Patients Controls OR (95% CI) p-value
n (%) n (%)
EAC rs6214 (IGF-I) GG 115 (32.9) 147 (42.1) Reference
GA 171 (48.9) 154 (44.1) 1.45 (1.04–2.01) 0.028
AA 64 (18.3) 48 (13.8) 1.71 (1.10–2.68) 0.018
rs6898743 (GHR) GG 189 (54.2) 199 (57.0) Reference
GC 137 (39.3) 133 (38.1) 1.10 (0.81–1.51) 0.540
CC 23 (6.6) 17 (4.9) 1.43 (0.74–2.78) 0.289
ESCC rs6214 (IGF-I) GG 39 (34.8) 35 (31.3) Reference
GA 54 (48.2) 60 (53.6) 0.80 (0.44–1.45) 0.450
AA 19 (17.0) 17 (15.2) 1.20 (0.53–2.74) 0.661
rs6898743 (GHR) GG 78 (69.6) 66 (58.9) Reference
GC 25 (22.3) 43 (38.4) 0.47 (0.26–0.86) 0.014
CC 9 (8.0) 3 (2.7) 2.54 (0.66–9.81) 0.175
Proximal CRC rs6214 (IGF-I) GG 51 (32.7) 55 (35.3) Reference
GA 82 (52.6) 74 (47.4) 1.20 (0.73–1.96) 0.481
AA 23 (14.7) 27 (17.3) 0.94 (0.48–1.86) 0.868
rs6898743 (GHR) GG 99 (63.5) 90 (57.7) Reference
GC 54 (34.6) 59 (37.8) 0.84 (0.53–1.34) 0.470
CC 3 (1.9) 7 (4.5) 0.39 (0.10–1.58) 0.188
Distal CRC rs6214 (IGF-I) GG 123 (33.6) 131 (35.8) Reference
GA 180 (49.2) 186 (50.8) 1.03 (0.74–1.41) 0.879
AA 63 (17.2) 49 (13.4) 1.37 (0.87–2.15) 0.173
rs6898743 (GHR) GG 217 (59.3) 220 (60.1) Reference
GC 126 (34.4) 119 (32.5) 1.09 (0.80–1.50) 0.581
CC 23 (6.3) 27 (7.4) 0.90 (0.50–1.62) 0.721
EAC, esophageal adenocarcinoma; ESCC, esophageal squamous cell carcinoma; CRC, colorectal cancer.
doi:10.1371/journal.pone.0090916.t005
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epithelium by specialized columnar-lined epithelium, and is one of
the main risk factors for EAC [27]. Therefore it is surprising that
we found a significant inverse association with EAC for the rs6214
GA and AA genotypes.
Two main explanations may be given: first, the patient group
with BE and the control group in the study of McElholm et al.
were relatively small (n = 207 and n=244, respectively). More
important however, is the large difference in allele frequencies,
being 48% and 52% for the rs6214 G and A alleles as reported by
McElholm et al. in their controls, whereas values of 57% and 43%
were reported for Europeans in the HAPMAP database [24]. The
latter values are in good agreement with our control allele
frequency data (60.5% G and 39.5% A allele).
The role of the genetic variant of rs6214 in pancreatic cancer in
a Japanese population was assessed by Nakao et al. [28]. Using AA
as the reference genotype, no association was found between
rs6214 and pancreatic cancer in the overall analysis, whereas 20
years old carriers of the GA and GG genotypes with a BMI $
25 kg/m2 showed an increased risk for pancreatic cancer.
However, the number of patients included in this sub-category
was very low and thus reliability is limited.
High plasma levels of IGF-I were suggested to be a risk for
various cancers, including CRC [29,30]. Therefore, Canzian
et al., Al-Zahrani et al. and D’Aloisio et al. investigated the role of
the rs6214 SNP on the circulating IGF-I levels in Caucasians
[20,31,32]. However, inconsistent results were obtained. In the
study of D’Aloisio et al., the AA genotype appeared to be
associated with high mean IGF-I plasma levels, whereas the other
two studies did not find an association between this SNP and
circulating IGF-I levels.
The SNP rs6898743 has not been extensively investigated so
far. Carriers of the CC genotypes were found inversely associated
with EAC by McElholm et al. [17], whereas our results showed a
tendency for the opposite. It was also remarkable that the allele
frequencies in the Irish study population as reported by McElholm
et al. [17] (19% G and 81% C for controls) were completely
different from the HAPMAP frequencies in the European
population [25] (77.9% G and 22.1% C). Our data of 76.9% G
allele and 23.1% C allele in controls completely fit with the
reported HAPMAP data for Europeans [25].
Some interesting gender related differences were found; in
women, genotype GA of SNP rs6214 was significantly associated
with GI- and HNC, whereas homozygosity for the variant C allele
of rs6898743 was inversely associated with HNC. In men, exactly
opposite effects were noticed, however results here are not
significant. It should be noticed however that the number of
female patients in the sub-group of HNC patients was small
(n = 93), which made the significance disputable.
The strength of the present study is that the patients and
controls were successfully matched by sex, race, recruiting area
and also largely by age. This enabled an assessment of association
between the SNPs and the outcomes, without being influenced by
Figure 1. Associations of the SNPs rs6214 and rs6898743 with gastrointestinal cancer. Only significant associations are visualized.
Associations are given as follows: rs number of the SNP, genotype, odds ratio with corresponding 95% confidence interval. The homozygous most
common genotype is taken as reference. EAC, esophageal adenocarcinoma; ESCC, esophageal squamous cell carcinoma.
doi:10.1371/journal.pone.0090916.g001
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these confounders. Moreover, the overall study population was
large.
This study also has its limitations. First of all, the matching by
age was not succeeded completely, as the mean ages between the
GI- and HNC patient and control groups differed significantly.
Therefore, unconditional logistic regression was used which
theoretically creates a lower power compared to conditional
logistic regression. Secondly, the ORs calculated in the sub-
analyses were not adjusted for multiple testing. This might be
advisable since multiple testing may increase the change to find a
significant association and thus creates bias. Thirdly, in this study
no information on smoking habits, alcohol consumption, diet and
other lifestyle factors is available. Furthermore, obesity of which
BMI and hip-to-waist ratio are suitable indicators, is an important
confounder for GI cancer [33]. Obesity may influence the risk of
colorectal cancer, and excess of body fat and fat distribution also
appeared to be related to EAC [33]. Co-morbidity, especially early
diagnosed diabetes mellitus, is associated with various cancers,
including cancers of the colorectum [34]. Moreover, in analyzing
the relationship between polymorphisms in the components of the
IGF axis and cancer in women, the use of birth control pills needs
to be taken into consideration, since the sex hormone estradiol has
a direct, as well as an indirect influence on the production of IGF-I
in estrogen-responsive tissues and the liver [35]. Other limitation
of this study is that the study populations in the sub-analyses were
relatively small, and that only one control was matched with one
patient.
In conclusion, the A allele of SNP rs6214 of the IGF-I gene is
associated with esophageal cancer. This association might be
mainly the result of effects on the histological subtype esophageal
adenocarcinoma in men. Furthermore, women with the A allele of
SNP rs6214 may have an increased risk for developing GI cancer,
more in particular HNC. These SNPs could be used as markers to
assess the cancer risk for these (histological) subtypes.
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